Renoprotective Properties of Angiotensin Receptor Blockers beyond Blood Pressure Lowering
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Clinical studies have demonstrated that some antihypertensive agents provide renoprotection independent of BP lowering. Recent in vitro and in vivo studies evaluated the mechanisms involved in this protection. First, the in vitro effects of several angiotensin II type 1 receptor blockers (ARB), calcium channel blockers (CCB), and beta blockers (BB) on various mediators were compared: Formation of pentosidine (an advanced glycation end product), hydroxyl radical-induced formation of o-tyrosine, and transition metals-induced oxidation of ascorbic acid (the Fenton reaction). All of the six tested ARB but neither the six CCB nor the nine BB inhibited pentosidine formation. ARB, as well as BB but not CCB, inhibited hydroxyl radicals-mediated o-tyrosine formation. ARB but neither BB nor CCB inhibited efficiently transition metals-catalyzed oxidation of ascorbic acid. Second, the in vivo consequences for the kidney of these various in vitro effects were evaluated. Hypertensive, type 2 diabetic rats with nephropathy, SHR/NDmcr-cp, were given for 20 wk either olmesartan (ARB) or nifedipine (CCB), or atenolol (BB). Despite similar BP reduction, only ARB significantly reduced proteinuria and prevented glomerular and tubulointerstitial damage (mesangial activation, podocyte injury, tubulointerstitial injury, and inflammatory cell infiltration). It is interesting that only ARB prevented abnormal iron deposition in the interstitium, corrected chronic hypoxia, reduced expressions of heme oxygenase and p47phox (a subunit of NADPHoxidase), and inhibited pentosidine formation (which correlates well with proteinuria). These observations confirm unique renoprotective properties of ARB, independent of BP lowering but related to decreased oxidative stress (hydroxyl radicals scavenging and inhibition of the Fenton reaction), correction of chronic hypoxia, and inhibition of advanced glycation end product formation and of abnormal iron deposition. These benefits of ARB may contribute to the renoprotection observed beyond BP lowering.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Bilirubin Is an Antioxidant of Possible Physiological Importance
Stocker, R., Yamamoto, Y., McDonagh, A. F., Glazer, A. N., & Ames, B. N. (1987) · Science · doi:10.1126/science.3029864 · Cited by 2,948 · cited 1×
“It protects against iron-induced tissue injury by generating the antioxidants biliverdin and bilirubin (39) or by modulating the levels of intracellular iron (40).”
Background[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., & Zucchelli, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341502 · Cited by 1,766
Heme oxygenase: Function, multiplicity, regulatory mechanisms, and clinical applications
Maines, M. D. (1988) · The FASEB Journal · doi:10.1096/fasebj.2.10.3290025 · Cited by 1,707 · cited 1×
“Oxidative Stress HO-1, one of the antioxidative renoprotective genes that are regulated by hypoxia (26,27), was expressed in a small number of tubules in WKY rats.”
BackgroundYan, S. D., Schmidt, A. M., Anderson, G. M., Zhang, J., Brett, J., Zou, Y. S., Pinsky, D., & Stern, D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36966-1 · Cited by 1,306
Jafar, T. H., Schmid, C. H., Landa, M., Giatras, I., Toto, R., Remuzzi, G., Maschio, G., Brenner, B. M., Kamper, A., Zucchelli, P., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-2-200107170-00007 · Cited by 1,092
Schrier, R. W., Estacio, R. O., Esler, A., & Mehler, P. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00213.x · Cited by 851
Viberti, G., & Wheeldon, N. M. (2002) · Circulation · doi:10.1161/01.cir.0000024416.33113.0a · Cited by 802
Lee, P. J., Jiang, B.-H., Chin, B. Y., Iyer, N. V., Alam, J., Semenza, G. L., & Choi, A. K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.9.5375 · Cited by 782 · cited 1×
“known to be enhanced by the hypoxia-inducible factor (36) as well as by abnormal iron deposition (37) and angiotensin II infusion (38).”
BackgroundNephropathy in Patients with Type 2 Diabetes Mellitus
Ritz, E., & Orth, S. R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910073411506 · Cited by 757
Nephropathy in Patients with Type 2 Diabetes
Remuzzi, G., Schieppati, A., & Ruggenenti, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp011773 · Cited by 587
Miyata, T., van Ypersele de Strihou, C., Kurokawa, K., & Baynes, J. W. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00302.x · Cited by 518
Self-citationHaem oxygenase-1 prevents cell death by regulating cellular iron
Ferris, C. D., Jaffrey, S. R., Sawa, A., Takahashi, M., Brady, S. D., Barrow, R. K., Tysoe, S. A., Wolosker, H., Barañano, D. E., Doré, S., et al. (1999) · Nature Cell Biology · doi:10.1038/11072 · Cited by 509
Johnson, R. J., Iida, H., Alpers, C. E., Majesky, M. W., Schwartz, S. M., Pritzi, P., Gordon, K., & Gown, A. M. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115089 · Cited by 460 · cited 1×
“-Smooth muscle actin (Figure 1D), a marker of mesangial injury and activation (25), was expressed in three to five glomeruli per section in SHR/NDmcr-cp rats that were given vehicle, nifedipine, or atenolol.”
McCance, D. R., Dyer, D. G., Dunn, J. A., Bailie, K. E., Thorpe, S. R., Baynes, J. W., & Lyons, T. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116482 · Cited by 444
Miyata, T., van Ypersele de Strihou, C., Ueda, Y., Ichimori, K., Inagi, R., Onogi, H., Ishikawa, N., Nangaku, M., & Kurokawa, K. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000032418.67267.f2 · Cited by 290 · cited 4×
“concentration of 10% does not influence the following assays (11).”
BackgroundSelf-citationInterstitial nephritis induced by protein-overload proteinuria.
Eddy, A. A. (1989) · Europe PMC (PubMed Central) · Cited by 286
Miyata, T., Hori, O., Zhang, J., Yan, S. D., Ferran, L., Iida, Y., & Schmidt, A. M. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118889 · Cited by 285
Self-citationForbes, J. M., Cooper, M. E., Thallas, V., Burns, W. C., Thomas, M. C., Brammar, G. C., Lee, F., Grant, S. L., Burrell, L. M., Jerums, G., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.11.3274 · Cited by 277
Renal diffusion and BOLD MRI in experimental diabetic nephropathy
Ries, M., Basseau, F., Tyndal, B., Jones, R., Deminière, C., Catargi, B., Combe, C., Moonen, C. W. T., & Grenier, N. (2003) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.10224 · Cited by 228 · cited 1×
“Its presence has been documented early in the evolution of diabetic kidneys (42).”
BackgroundEvidence of Tubular Hypoxia in the Early Phase in the Remnant Kidney Model
Manotham, K., Tanaka, T., Matsumoto, M., Ohse, T., Miyata, T., Inagi, R., Kurokawa, K., Fujita, T., & Nangaku, M. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000125614.35046.10 · Cited by 226 · cited 1×
“Norman’s group (44) and ours (45) have shown independently that RAS blockade improves tubulointerstitial hypoxia.”
BackgroundSelf-citationFormation of o-tyrosine and dityrosine in proteins during radiolytic and metal-catalyzed oxidation
Huggins, T. G., Wells-Knecht, M. C., Detorie, N. A., Baynes, J. W., & Thorpe, S. R. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)31395-4 · Cited by 223
Role of iron in postischemic renal injury in the rat
Paller, M. S., Hedlund, B. E., Sikora, J. J., Faassen, A., & Waterfield, R. (1988) · Kidney International · doi:10.1038/ki.1988.205 · Cited by 222
Heme protein-induced chronic renal inflammation: Suppressive effect of induced heme oxygenase-1
Nath, K. A., Vercellotti, G. M., Grande, J. P., Miyoshi, H., Paya, C. V., Manivel, J. C., Haggard, J. J., Croatt, A. J., Payne, W. D., & Alam, J. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00471.x · Cited by 211 · cited 1×
“known to be enhanced by the hypoxia-inducible factor (36) as well as by abnormal iron deposition (37) and angiotensin II infusion (38).”
BackgroundBAKRIS, G., BANK, A., KASS, D., NEUTEL, J., PRESTON, R., & OPARIL, S. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.08.022 · Cited by 210
Imbalance of T-Cell Subsets in Angiotensin II–Infused Hypertensive Rats With Kidney Injury
Shao, J., Nangaku, M., Miyata, T., Inagi, R., Yamada, K., Kurokawa, K., & Fujita, T. (2003) · Hypertension · doi:10.1161/01.hyp.0000075082.06183.4e · Cited by 210 · cited 1×
“Alternatively, olmesartan might correct an imbalance between helper T cell subsets followed by an ameliorated tubulointerstitial inflammation, as observed after angiotensin II infusion in another hypertensive kidney injury model (46).”
BackgroundSelf-citationTransdifferentiation of cultured tubular cells induced by hypoxia
Manotham, K., Tanaka, T., Matsumoto, M., Ohse, T., Inagi, R., Miyata, T., Kurokawa, K., Fujita, T., Ingelfinger, J. R., & Nangaku, M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00461.x · Cited by 202 · cited 1×
“Chronic hypoxia in the tubulointerstitial tissue transforms tubular cells into myofibroblasts and accelerates tissue fibrosis (49), which is further exacerbated by concomitant inflammatory cells infiltration, oxidative matrix protein damage, and AGE modification.”
BackgroundSelf-citationMiyata, T., Taneda, S., Kawai, R., Ueda, Y., Horiuchi, S., Hara, M., Maeda, K., & Monnier, V. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.6.2353 · Cited by 191
Self-citationDiabetic Nephropathy: Can Renoprotection Be Extrapolated to Cardiovascular Protection?
Opie, L. H., & Parving, H.-H. (2002) · Circulation · doi:10.1161/01.cir.0000028099.24188.c4 · Cited by 178
Nangaku, M., Miyata, T., Sada, T., Mizuno, M., Inagi, R., Ueda, Y., Ishikawa, N., Yuzawa, H., Koike, H., van Ypersele de Strihou, C., et al. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000062961.76776.c1 · Cited by 173 · cited 4×
“The previously used (19) male subline of spontaneously”
BackgroundMethodSelf-citationAizawa, T., Ishizaka, N., Taguchi, J., Nagai, R., Mori, I., Tang, S., Ingelfinger, J. R., & Ohno, M. (2000) · Hypertension · doi:10.1161/01.hyp.35.3.800 · Cited by 160
Self-citationZhou, X. J., Laszik, Z. G., Wang, X. Q., Silva, F. G., & Vaziri, N. D. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780200 · Cited by 144
Horie, K., Miyata, T., Yasuda, T., Takeda, A., Yasuda, Y., Maeda, K., Sobue, G., & Kurokawa, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6944 · Cited by 137
Self-citationIron Accumulation in Human Chronic Renal Disease
Nankivell, B. J., Boadle, R. A., & Harris, D. C. H. (1992) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)70222-6 · Cited by 118
Hypoxia in Renal Disease with Proteinuria and/or Glomerular Hypertension
Tanaka, T., Miyata, T., Inagi, R., Fujita, T., & Nangaku, M. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63249-x · Cited by 114
Self-citationRole of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis
Alfrey, A. C., Froment, D. H., & Hammond, W. S. (1989) · Kidney International · doi:10.1038/ki.1989.259 · Cited by 110
Floege, J., Alpers, C. E., Sage, E. H., Pritzl, P., Gordon, K. R., Johnson, R. J., & Couser, W. G. (1992) · PubMed · Cited by 107
Baba, S. (2001) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(01)00288-1 · Cited by 104
Norman, J. T., Stidwill, R. P., Singer, M., & Fine, L. G. (2003) · Nephron Physiology · doi:10.1159/000071289 · Cited by 104 · cited 1×
“Norman’s group (44) and ours (45) have shown independently that RAS blockade improves tubulointerstitial hypoxia.”
BackgroundCytoprotective role of heme oxygenase (HO)-1 in human kidney with various renal diseases
Morimoto, K., Ohta, K., Yachie, A., Yang, Y., Shimizu, M., Goto, C., Toma, T., Kasahara, Y., Yokoyama, H., Miyata, T., et al. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.01000.x · Cited by 104 · cited 1×
“Oxidative Stress HO-1, one of the antioxidative renoprotective genes that are regulated by hypoxia (26,27), was expressed in a small number of tubules in WKY rats.”
BackgroundSelf-citationBlood oxygen level dependent (BOLD) MRI: A novel technique for the detection of myocardial ischemia
Egred, M., Waiter, G. D., Al‐Mohammad, A., Semple, S. I. K., Redpath, T. W., & Walton, S. P. (2006) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2006.04.015 · Cited by 88
Microvascular and tubulointerstitial injury associated with chronic hypoxia-induced hypertension
Mazzali, M., Jefferson, J. A., Ni, Z., Vaziri, N. D., & Johnson, R. J. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00011.x · Cited by 77
Transition metals redox: reviving an old plot for diabetic vascular disease
Monnier, V. M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12635 · Cited by 55 · cited 2×
“The Fenton reaction catalyzed by transition metal ions (copper and iron) is critical in oxidative biochemistry to generate hydroxyl radicals (22).”
BackgroundOkamura, N., BABIOR, B. M., Mayo, L., Peveri, P., Smith, R. M., & Curnutte, J. T. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114608 · Cited by 40
Abnormal Iron Deposition in Renal Cells in the Rat with Chronic Angiotensin II Administration
Ishizaka, N., Aizawa, T., Yamazaki, I., Usui, S.-I., Mori, I., Kurokawa, K., Tang, S., Ingelfinger, J. R., Ohno, M., & Nagai, R. (2002) · Laboratory Investigation · doi:10.1038/labinvest.3780398 · Cited by 38
Self-citationUrinary concentrating defect in experimental hemochromatosis.
Zhou, X., Vaziri, N. D., Pandian, D. V., Wang, Z. Q., Mazowiecki, M., Liao, S. Y., & Oveisi, F. (1996) · Journal of the American Society of Nephrology · doi:10.1681/asn.v71128 · Cited by 19
Cited by
Pharmacological and Clinical Aspects of Heme Oxygenase
Abraham, N. G., & Kappas, A. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07104 · Cited by 1,115
“…properties have been proposed for angiotensin receptor blockers independent of blood pressure lowering but related to decreased oxidative stress, correction of chronic hypoxia, and inhibition of advanced glycation end product formation and of abnormal iron deposition (Izuhara et al., 2005).”
The proximal tubule in the pathophysiology of the diabetic kidney
Vallon, V. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00809.2010 · Cited by 395
Microemulsions as carriers for drugs and nutraceuticals
Spernath, A., & Aserin, A. (2006) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2006.11.016 · Cited by 325
The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease
Mimura, I., & Nangaku, M. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.124 · Cited by 302
Self-citationOxidants in Chronic Kidney Disease
Shah, S. V., Baliga, R., Rajapurkar, M., & Fonseca, V. A. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050500 · Cited by 276
Metadata
- Authors
- Izuhara, Y., Nangaku, M., Inagi, R., Tominaga, N., Aizawa, T., Kurokawa, K., van Ypersele de Strihou, C., & Miyata, T.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2005-12
- Volume
- 16
- Issue
- 12
- Pages
- 3631-3641
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2151788147
- Cited by
- 188
- References
- 48
- FWCI
- 12.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.